157 related articles for article (PubMed ID: 36835617)
21. Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.
Richard C; Fumet JD; Chevrier S; Derangère V; Ledys F; Lagrange A; Favier L; Coudert B; Arnould L; Truntzer C; Boidot R; Ghiringhelli F
Clin Cancer Res; 2019 Feb; 25(3):957-966. PubMed ID: 30154227
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
23. Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.
Parra ER; Zhang J; Duose DY; Gonzalez-Kozlova E; Redman MW; Chen H; Manyam GC; Kumar G; Zhang J; Song X; Lazcano R; Marques-Piubelli ML; Laberiano-Fernandez C; Rojas F; Zhang B; Taing L; Jhaveri A; Geisberg J; Altreuter J; Michor F; Provencher J; Yu J; Cerami E; Moravec R; Kannan K; Luthra R; Alatrash G; Huang HH; Xie H; Patel M; Nie K; Harris J; Argueta K; Lindsay J; Biswas R; Van Nostrand S; Kim-Schulze S; Gray JE; Herbst RS; Wistuba II; Gettinger S; Kelly K; Bazhenova L; Gnjatic S; Lee JJ; Zhang J; Haymaker C
Clin Cancer Res; 2024 Apr; 30(8):1655-1668. PubMed ID: 38277235
[TBL] [Abstract][Full Text] [Related]
24. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
[TBL] [Abstract][Full Text] [Related]
25. A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA).
Meindl-Beinker NM; Betge J; Gutting T; Burgermeister E; Belle S; Zhan T; Schulte N; Maenz M; Ebert MP; Haertel N
BMC Cancer; 2019 Mar; 19(1):231. PubMed ID: 30871493
[TBL] [Abstract][Full Text] [Related]
26. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.
Bestvina CM; Pointer KB; Karrison T; Al-Hallaq H; Hoffman PC; Jelinek MJ; Juloori A; Melotek JM; Murgu S; Partouche J; Vokes EE; Weichselbaum RR; Pitroda SP; Patel JD; Chmura SJ
J Thorac Oncol; 2022 Jan; 17(1):130-140. PubMed ID: 34500113
[TBL] [Abstract][Full Text] [Related]
27. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.
Borghaei H; Ciuleanu TE; Lee JS; Pluzanski A; Caro RB; Gutierrez M; Ohe Y; Nishio M; Goldman J; Ready N; Spigel DR; Ramalingam SS; Paz-Ares LG; Gainor JF; Ahmed S; Reck M; Maio M; O'Byrne KJ; Memaj A; Nathan F; Tran P; Hellmann MD; Brahmer JR
Ann Oncol; 2023 Feb; 34(2):173-185. PubMed ID: 36414192
[TBL] [Abstract][Full Text] [Related]
28. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
[TBL] [Abstract][Full Text] [Related]
29. Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
DeLeon TT; Almquist DR; Kipp BR; Langlais BT; Mangold A; Winters JL; Kosiorek HE; Joseph RW; Dronca RS; Block MS; McWilliams RR; Kottschade LA; Rumilla KM; Voss JS; Seetharam M; Sekulic A; Markovic SN; Bryce AH
PLoS One; 2020; 15(3):e0230306. PubMed ID: 32196516
[TBL] [Abstract][Full Text] [Related]
30. Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations.
Kauffmann-Guerrero D; Tufman A; Kahnert K; Bollmann BA; Reu S; Syunyaeva Z; Schneider C; Manapov F; Huber RM; Golpon H
Oncol Res Treat; 2020; 43(6):289-298. PubMed ID: 32268332
[TBL] [Abstract][Full Text] [Related]
31. Nivolumab for the treatment of small cell lung cancer.
Simeone E; Grimaldi AM; Festino L; Trojaniello C; Vitale MG; Vanella V; Curvietto M; Ascierto PA
Expert Rev Respir Med; 2020 Jan; 14(1):5-13. PubMed ID: 31622114
[No Abstract] [Full Text] [Related]
32. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
Wagner MJ; Othus M; Patel SP; Ryan C; Sangal A; Powers B; Budd GT; Victor AI; Hsueh CT; Chugh R; Nair S; Leu KM; Agulnik M; Sharon E; Mayerson E; Plets M; Blanke C; Streicher H; Chae YK; Kurzrock R
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34380663
[TBL] [Abstract][Full Text] [Related]
33. Indirect comparison of pembrolizumab monotherapy versus nivolumab + ipilimumab in first-line metastatic lung cancer.
Halmos B; Burke T; Kalyvas C; Insinga R; Vandormael K; Frederickson A; Piperdi B
Immunotherapy; 2022 Apr; 14(5):295-307. PubMed ID: 35073727
[No Abstract] [Full Text] [Related]
34. Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma.
Grimm MO; Schmitz-Dräger BJ; Zimmermann U; Grün CB; Baretton GB; Schmitz M; Foller S; Leucht K; Schostak M; Zengerling F; Schumacher U; Loidl W; Meran J
J Clin Oncol; 2022 Jul; 40(19):2128-2137. PubMed ID: 35275706
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.
Carreau NA; Pavlick AC
Future Oncol; 2019 Feb; 15(4):349-358. PubMed ID: 30334646
[TBL] [Abstract][Full Text] [Related]
36. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
37. Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer.
Kasi PM; Budde G; Krainock M; Aushev VN; Koyen Malashevich A; Malhotra M; Olshan P; Billings PR; Aleshin A
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101943
[TBL] [Abstract][Full Text] [Related]
38. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
39. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
Jiang T; Shi J; Dong Z; Hou L; Zhao C; Li X; Mao B; Zhu W; Guo X; Zhang H; He J; Chen X; Su C; Ren S; Wu C; Zhou C
J Hematol Oncol; 2019 Jul; 12(1):75. PubMed ID: 31299995
[TBL] [Abstract][Full Text] [Related]
40. A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma.
Pothuri V; Herndon J; Ballentine SJ; Lim KH; Fields RC
Oncologist; 2021 Sep; 26(9):722-726. PubMed ID: 33982365
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]